Owens, S.M., and Mayershohn, M. (1986). Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metabolism and Disposition, 14(1), 52-58.

Petrakis, I.L., Carroll, K.M., Nich, C., Gordon, L.T., McCance-Katz, E.F., Frankforter, T., and Rounsaville, B.J. (2000). Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction, 95(2), 219-228.

Petry, N.M., and Bickel, W.K. (1998). Polydrug abuse in heroin addicts: A behavioral economic analysis. Addiction, 93(3), 321-335.

Pettinati, H.M., Volpicelli, J.R., Kranzler, H.R., Luck, G., Rukstalis, M.R., and Cnaan, A. (2000). Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcoholism, Clinical and Experimental Research, 24(7), 1041-1049.

Proksch, J.W., Gentry, W.B., and Owens, S.M. (2000). Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. Journal of Pharmacology and Experimental Therapeutics, 292(3), 831-837.

Reh, M. (1998). Changes at FDA may speed drug approval process and increase off-label use. Journal of the National Cancer Institute, 90(11), 805-807.

Rosenheck, R., and Kosten, T. (2001). Buprenorphine for opiate addiction: Potential economic impact. Drug and Alcohol Dependence, 63(3), 253-262.

Sims, T.H., and Fiore, M.C. (2002). Pharmacotherapy for treating tobacco dependence: What is the ideal duration of therapy? CNS Drugs, 16(10), 653-662.

Sindelar, J.L., and Fiellin, D.A. (2001). Innovations in treatment for drug abuse: Solutions to a public health problem. Annual Review of Public Health, 22, 249-272.

Singh, P.K., and Richell-Herren, K. (2000). Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. Flumazenil and suspected benzodiazepine overdose. Journal of Accident and Emergency Medicine, 17(3), 214.

Sparenborg, S., Vocci, F., and Zukin, S. (1997). Peripherial cocaine-blocking agents: New medications for cocaine dependence. Drug and Alcohol Dependence, 48(3), 149-151.

Srisurapanont, M., and Jarusuraisin, N. (2004). Opioid antagonists for alcohol dependence. In The Cochrane Library (Issue 1). Chichester, England: John Wiley & Sons.

Streeton, C., and Whelan, G. (2001). Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol and Alcoholism, 36(6), 544-552.

Sullivan, M.A., and Covey, L.S. (2002). Nicotine dependence: The role for antidepressants and anxiolytics. Current Opinion in Investigational Drugs, 3(2), 262-271.

Sutherland, G. (2002). Current approaches to the management of smoking cessation. Drugs, 62(Suppl 2), 53-61.

Swanson, J.M., and Volkow, N.D. (2002). Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behavioural Brain Research, 130(1-2), 73-78.

Valentine, J.L., Mayersohn, M., Wessinger, W.D., Arnold, L.W., and Owens, S.M. (1996). Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. Journal of Pharmacology and Experimental Therapeutics, 278(2), 709-716.

Volpicelli, J., O’Brien, C., Alterman, A., and Hayashida, M. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49(11), 867-880.

Woolacott, N.F., Jones, L., Forbes, C.A., Mather, L.C., Sowden, A.J., Song, F.J., Raftery, J.P., Aveyard, P.N., Hyde, C.J., and Barton, P.M. (2002). The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation. Health Technology Assessment, 6(16), 1-245.

Wright, C., and Moore, R.D. (1990). Disulfiram treatment of alcoholism. American Journal of Medicine, 88(6), 647-655.